PlasmarkAD®, a blood test that simultaneously measures 21 blood protein biomarkers leveraging cutting-edge proteomics technology and self-developed machine learning algorithm. Launched in Hong Kong in July 2023, it was developed by a research team at the Hong Kong University of Science and Technology and licensed to Cognitact Limited for further development and commercialization. This innovative test detects AD 5-10 years before symptoms manifest with an accuracy of 96 per cent through a simple blood draw. Moreover, it provides a multi-dimensional analysis of various body systems that may be affected by AD, including the immune, metabolic, nervous and vascular systems, enabling personalised analysis and recommendations.